Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MN-166 (Ibudilast) in ALS (COMBAT-ALS)
NCT04057898Phase 3Active, not recruiting
- Sponsor
- MediciNova, Inc.
- Start
- May 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ibudilast in amyotrophic lateral sclerosis (ALS), sponsored by MediciNova, Inc.. Started May 2020; status: active, not recruiting.
02
Drugs
ibudilast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04057898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057898.